World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience

American Journal of Hematology

Volumn 88, Issue 12, 2013, Pages 1012-1016

  Madelung, Ann Brinch ^a   Bondo, Henrik ^a   Stamp, Inger ^a   Loevgreen, Preben ^b   Nielsen, Signe Ledou ^c   Falensteen, Anne ^c   Knudsen, Helle ^c   Ehinger, Mats ^d   Dahl Sørensen, Rasmus ^b   Mortensen, Nana Brochmann ^b   Svendsen, Kira Dynnes ^e   Lange, Theis ^e   Ralfkiaer, Elisabeth ^f   Nielsen, Karsten ^a   Hasselbalch, Hans Carl ^b   Thiele, Jürgen ^g  

^a NAESTVED HOSPITAL   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Mental Health Center Glostrup   (Denmark)

^g UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CLINICAL EVALUATION; CONSENSUS; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MORPHOLOGY; MYELOID LEUKEMIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PATHOLOGIST; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION;

AGED; BONE MARROW; BONE MARROW EXAMINATION; CONSENSUS; DENMARK; FEMALE; HUMANS; LABORATORY PROFICIENCY TESTING; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; OBSERVER VARIATION; PATHOLOGY DEPARTMENT, HOSPITAL; PATHOLOGY, CLINICAL; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; SINGLE-BLIND METHOD; SWEDEN; WORLD HEALTH ORGANIZATION;

EID: 84888053932     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23554     Document Type: Article

References (27)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114(5):937-951.
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110(4):1092-1097.
3. Brousseau M, Parot-Schinkel E, Moles MP, et al. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010;56(6):758-767.
4. Buhr T, Hebeda K, Kaloutsi V, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-365.
5. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal. Blood 2008;112(2):231-239.
6. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood 2008;111(1):60-70.
7. Aumann K, Frey AV, May AM, et al. Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. Blood 2013;122(1):93-99.
8. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011;29(23):3179-3184.
9. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013 doi: 10.1038/leu.2013.163. [Epub ahead of print].
10. Florena AM, Tripodo C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89(8):911-919.
11. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006;47(9):1774-1781.
12. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features-A clinicopathological study on 272 patients. Histol Histopathol 2003;18(1):93-102.
13. Thiele J, Kvasnicka HM, Mullauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification. Blood 2011;117(21):5710-5718.
14. Koopmans SM, Bot FJ, Lam KH, et al. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am J Clin Pathol 2011;136(4):618-624.
15. Michielis JJ, Kvasnicka HM, Thiele J. Myeloproliferative Disorders: Current Perspectives on Diagnostic Criteria, Histopathology, and Treatment in Essential Thrombocythemia, Polycythemia Rubra Vera, and Chronic Idiopathic Myelofibrosis. Much, Germany: ME-UWe Grunwald Publishing; 2005. 112pp.
16. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90(8):1128-1132.
17. Kirkwood BR, Sterne J. Essential Medical Statistics. MA: Blackwell Publishing; 2003. 480pp.
18. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. New York: John Wiley and Sons Ltd; 2003. 800pp.
19. Gwet K. Inter-Rater Reliability: Dependency on Trait Prevalence and Marginal Homogeneity. Statistical Methods For Inter-Rater Reliability Assessment, No 2. Gaithersburg, MD: STATAXIS Consulting; 2002.
20. Lones MA, Auperin A, Raphael M, et al. Mature B-cell lymphoma/leukemia in children and adolescents: Intergroup pathologist consensus with the revised European-American Lymphoma Classification. Ann Oncol 2000;11(1):47-51.
21. Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma: A clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 2002;43(1):97-104.
22. Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13(1):140-149.
23. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: A follow-up study on 309 patients. Leuk Lymphoma 2003;44(6):949-953.
24. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 2006;85(4):226-232.
25. Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012;7(4):e35631.
26. Buhr T, Busche G, Choritz H, et al. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003;119(1):152-158.
27. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22(2):437-438.